Rezolute Inc (RZLT)

$5.95 -0.06 (-1.00%)
Market Cap 522.85M
Revenue (ttm) 0.00
Net Income (ttm) -68.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 516,600
Avg Vol 1,159,464
Day's Range N/A - N/A
Shares Out 87.00M
Stochastic %K 51%
Beta 1.03
Analysts Strong Sell
Price Target $13.25

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabet...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
Luhbonkers
Luhbonkers Jul. 31 at 8:16 PM
$RZLT buying here
0 · Reply
oaksapollo
oaksapollo Jul. 29 at 5:33 PM
$RZLT They're letting it rest today, look at the super low volume. When the volume comes back >1M, we'll be hitting new highs.
0 · Reply
riskmit
riskmit Jul. 28 at 2:15 PM
$RZLT under the radar #stealth
0 · Reply
Monty3030
Monty3030 Jul. 27 at 7:03 PM
$RZLT Could we see a possible double-digit price this week?
0 · Reply
GollumSmeagol
GollumSmeagol Jul. 25 at 8:03 PM
$RZLT New 52 week high, boom!
0 · Reply
GollumSmeagol
GollumSmeagol Jul. 25 at 4:11 PM
$RZLT Wow running, wasn’t expecting this till closer to data. Happy nonetheless, LFG!
1 · Reply
oaksapollo
oaksapollo Jul. 25 at 3:52 PM
$RZLT this is creeping up on very little volume. If the volume comes back, LOOKOUT, this will blast off.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Jul. 25 at 2:50 PM
$RZLT This one deserves more ❤️ What a beast
0 · Reply
Monty3030
Monty3030 Jul. 25 at 2:29 PM
$RZLT This might get epic next week!
0 · Reply
MGeronimo
MGeronimo Jul. 25 at 3:16 AM
$RZLT NEW 52 week high as called
2 · Reply
Latest News on RZLT
Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Jul 22, 2025, 7:30 AM EDT - 10 days ago

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Jul 9, 2025, 7:30 AM EDT - 23 days ago

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025, 8:00 AM EDT - 2 months ago

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 2 months ago

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025, 8:00 AM EDT - 3 months ago

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute to Participate in Upcoming Investor Conferences

May 1, 2025, 8:00 AM EDT - 3 months ago

Rezolute to Participate in Upcoming Investor Conferences

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025, 3:57 AM EDT - 3 months ago

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

Rezolute, Inc. Announces Closing of Underwritten Offering

Apr 25, 2025, 4:30 PM EDT - 3 months ago

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Apr 23, 2025, 3:50 PM EDT - 3 months ago

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Apr 23, 2025, 8:05 AM EDT - 3 months ago

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Apr 23, 2025, 8:00 AM EDT - 3 months ago

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Mar 26, 2025, 7:30 AM EDT - 4 months ago

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Feb 18, 2025, 1:30 AM EST - 5 months ago

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 4:05 PM EST - 6 months ago

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Feb 4, 2025, 8:00 AM EST - 6 months ago

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 8:00 AM EST - 6 months ago

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2024, 8:00 AM EST - 8 months ago

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Dec 3, 2024, 3:56 PM EST - 8 months ago

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 19, 2024, 4:05 PM EDT - 11 months ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

Sep 9, 2024, 10:41 AM EDT - 11 months ago

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

Sep 9, 2024, 7:47 AM EDT - 11 months ago

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Sep 9, 2024, 7:30 AM EDT - 11 months ago

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Jun 13, 2024, 11:30 PM EDT - 1 year ago

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rezolute to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Rezolute to Participate in the Jefferies Global Healthcare Conference

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

May 21, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 15, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Mar 6, 2024, 7:30 AM EST - 1 year ago

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Feb 13, 2024, 4:05 PM EST - 1 year ago

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

Jan 24, 2024, 8:00 AM EST - 1 year ago

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Jan 23, 2024, 8:00 AM EST - 1 year ago

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Dec 14, 2023, 8:00 AM EST - 1 year ago

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Dec 13, 2023, 8:00 AM EST - 1 year ago

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

Nov 24, 2023, 11:14 AM EST - 1 year ago

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Nov 17, 2023, 8:00 AM EST - 1 year ago

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Rezolute Reports First Quarter Fiscal 2024 Results

Nov 13, 2023, 4:05 PM EST - 1 year ago

Rezolute Reports First Quarter Fiscal 2024 Results

Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study

Nov 9, 2023, 6:57 PM EST - 1 year ago

Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Sep 14, 2023, 4:05 PM EDT - 2 years ago

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Rezolute to Participate in Upcoming Investor Conferences in September

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Rezolute to Participate in Upcoming Investor Conferences in September

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Jun 27, 2023, 4:05 PM EDT - 2 years ago

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

Jun 1, 2023, 12:45 PM EDT - 2 years ago

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

OCS

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

May 11, 2023, 4:05 PM EDT - 2 years ago

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

Mar 23, 2023, 4:50 PM EDT - 2 years ago

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

Mar 8, 2023, 7:00 AM EST - 2 years ago

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

Luhbonkers
Luhbonkers Jul. 31 at 8:16 PM
$RZLT buying here
0 · Reply
oaksapollo
oaksapollo Jul. 29 at 5:33 PM
$RZLT They're letting it rest today, look at the super low volume. When the volume comes back >1M, we'll be hitting new highs.
0 · Reply
riskmit
riskmit Jul. 28 at 2:15 PM
$RZLT under the radar #stealth
0 · Reply
Monty3030
Monty3030 Jul. 27 at 7:03 PM
$RZLT Could we see a possible double-digit price this week?
0 · Reply
GollumSmeagol
GollumSmeagol Jul. 25 at 8:03 PM
$RZLT New 52 week high, boom!
0 · Reply
GollumSmeagol
GollumSmeagol Jul. 25 at 4:11 PM
$RZLT Wow running, wasn’t expecting this till closer to data. Happy nonetheless, LFG!
1 · Reply
oaksapollo
oaksapollo Jul. 25 at 3:52 PM
$RZLT this is creeping up on very little volume. If the volume comes back, LOOKOUT, this will blast off.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Jul. 25 at 2:50 PM
$RZLT This one deserves more ❤️ What a beast
0 · Reply
Monty3030
Monty3030 Jul. 25 at 2:29 PM
$RZLT This might get epic next week!
0 · Reply
MGeronimo
MGeronimo Jul. 25 at 3:16 AM
$RZLT NEW 52 week high as called
2 · Reply
Monty3030
Monty3030 Jul. 24 at 1:43 PM
$RZLT
0 · Reply
oaksapollo
oaksapollo Jul. 24 at 1:38 PM
$RZLT man something is up, Aug $7.50 calls trading at $0.20 this morning!?
0 · Reply
biolevity
biolevity Jul. 24 at 1:33 PM
$RZLT could be the $SLNO
0 · Reply
Hertha
Hertha Jul. 24 at 2:39 AM
$RZLT A lot of technical traders here. Anyone read what they like to achieve? It will 20x once they get approval. There are no competitors If buying a lottery ticket, know what they can achieve
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Jul. 23 at 2:47 PM
$RZLT
0 · Reply
Monty3030
Monty3030 Jul. 23 at 2:34 PM
$RZLT
0 · Reply
Badcuda2
Badcuda2 Jul. 21 at 9:24 PM
$RZLT I still like the company , just pointing out what’s happening as the price goes up . Surprised to read about Rz-402 progress , this will make the company rich
1 · Reply
oaksapollo
oaksapollo Jul. 21 at 2:58 PM
$RZLT seems like just about every day, a small biotech is getting acquired. Today it's ITOS. One of these days it will be RZLT. There is no reason for big pharma to wait for the data in December and pay a lot more. Between the phase 3 interim analysis, the strong phase 2 data, and the recently released data showing that there is no difference in phase 3 patient population vs phase 2, this is very de-risked and ready to be acquired. That being said, if they want to wait, this goes to $10 on phase 3 results, and then they acquire for $20, that is fine by me!
1 · Reply
Monty3030
Monty3030 Jul. 18 at 1:53 PM
$RZLT Breakout confirmed!! Now let's see where we go!
1 · Reply
lisaparsons
lisaparsons Jul. 17 at 9:31 PM
$RZLT share offering. Shit
1 · Reply
Monty3030
Monty3030 Jul. 17 at 7:49 PM
$RZLT Once we break $5.62 we're going to a new 52 week high!
0 · Reply
oaksapollo
oaksapollo Jul. 17 at 3:06 PM
$RZLT bought some Aug $5 calls for $0.65. Seemed like too good of a deal to pass up. Now let's get acquired or stop the study for overwhelming efficacy in the next 4 weeks please :-)
0 · Reply